These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 27142424)

  • 1. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
    De Divitiis C; von Arx C; Grimaldi AM; Cicala D; Tatangelo F; Arcella A; Romano GM; Simeone E; Iaffaioli RV; Ascierto PA; Tafuto S;
    J Transl Med; 2016 May; 14(1):113. PubMed ID: 27142424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
    Welin S; Sorbye H; Sebjornsen S; Knappskog S; Busch C; Oberg K
    Cancer; 2011 Oct; 117(20):4617-22. PubMed ID: 21456005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
    Fazio N; Spada F; Giovannini M
    Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
    Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
    BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT.
    Park HJ; Kim HJ; Kim KW; Kim SY; Choi SH; You MW; Hwang HS; Hong SM
    Eur Radiol; 2020 Sep; 30(9):4772-4782. PubMed ID: 32346794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
    Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
    Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
    Rinke A; Gress TM
    Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
    Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
    World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice.
    Bruera G; Giuliani A; Romano L; Chiominto A; Di Sibio A; Mastropietro S; Cosenza P; Ricevuto E; Schietroma M; Carlei F;
    BMC Cancer; 2019 Oct; 19(1):960. PubMed ID: 31619203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial.
    von Arx C; Della Vittoria Scarpati G; Cannella L; Clemente O; Marretta AL; Bracigliano A; Picozzi F; Iervolino D; Granata V; Modica R; Bianco A; Mocerino C; Di Mauro A; Pizzolorusso A; Di Sarno A; Ottaiano A; Tafuto S;
    ESMO Open; 2024 May; 9(5):103003. PubMed ID: 38615472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
    Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
    Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological imaging and CT histogram analysis to differentiate pancreatic neuroendocrine tumor grade 3 from neuroendocrine carcinoma.
    Azoulay A; Cros J; Vullierme MP; de Mestier L; Couvelard A; Hentic O; Ruszniewski P; Sauvanet A; Vilgrain V; Ronot M
    Diagn Interv Imaging; 2020 Dec; 101(12):821-830. PubMed ID: 32709455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
    Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
    Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
    Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
    Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
    Klöppel G
    Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.